News Updates

More Articles Back to Article

Ariceum raises funds for satoreotide development

Ariceum Therapeutics raised $26.7 million from a Series A funding round to develop its main radiopharmaceutical drug. Satoreotide is being developed to use in the diagnosis and treatment of tumors expressing the somatostatin type 2 receptor, and Ariceum aims to have three clinical trials underway next year. Endpoints News (free registration) (6/8)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!